Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain. 2017

Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

Simian immunodeficiency viruses (SIVs) use their Nef proteins to counteract the restriction factor tetherin. However, a deletion in human tetherin prevents antagonism by the Nef proteins of SIVcpz and SIVgor, which represent the ape precursors of human immunodeficiency virus type 1 (HIV-1). To promote virus release from infected cells, pandemic HIV-1 group M strains evolved Vpu as a tetherin antagonist, while the Nef protein of less widespread HIV-1 group O strains acquired the ability to target a region adjacent to this deletion. In this study, we identified an unusual HIV-1 group O strain (RBF206) that evolved Vpu as an effective antagonist of human tetherin. While both RBF206 Vpu and Nef exert anti-tetherin activity in transient-transfection assays, mainly Vpu promotes RBF206 release in infected CD4+ T cells. Although mutations distinct from the adaptive changes observed in group M Vpus (M-Vpus) were critical for the acquisition of its anti-tetherin activity, RBF206 O-Vpu potently suppresses NF-κB activation and reduces CD4 cell surface expression. Interestingly, RBF206 Vpu counteracts tetherin in a largely species-independent manner, degrading both the long and short isoforms of human tetherin. Downmodulation of CD4, but not counteraction of tetherin, by RBF206 Vpu was dependent on the cellular ubiquitin ligase machinery. Our data present the first example of an HIV-1 group O Vpu that efficiently antagonizes human tetherin and suggest that counteraction by O-Nefs may be suboptimal.IMPORTANCE Previous studies showed that HIV-1 groups M and O evolved two alternative strategies to counteract the human ortholog of the restriction factor tetherin. While HIV-1 group M switched from Nef to Vpu due to a deletion in the cytoplasmic domain of human tetherin, HIV-1 group O, which lacks Vpu-mediated anti-tetherin activity, acquired a Nef protein that is able to target a region adjacent to the deletion. Here we report an unusual exception, identifying a strain of HIV-1 group O (RBF206) whose Vpu protein evolved an effective antagonism of human tetherin. Interestingly, the adaptive changes in RBF206 Vpu are distinct from those found in M-Vpus and mediate efficient counteraction of both the long and short isoforms of this restriction factor. Our results further illustrate the enormous flexibility of HIV-1 in counteracting human defense mechanisms.

UI MeSH Term Description Entries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D054298 Human Immunodeficiency Virus Proteins Proteins synthesized by HUMAN IMMUNODEFICIENCY VIRUSES such as the HIV-1 and HIV-2. HIV Proteins,HIV Gene Products,Human Immunodeficiency Virus Gene Products
D054334 Viral Regulatory and Accessory Proteins A broad category of viral proteins that play indirect roles in the biological processes and activities of viruses. Included here are proteins that either regulate the expression of viral genes or are involved in modifying host cell functions. Many of the proteins in this category serve multiple functions. Viral Accessory Proteins,Viral Regulatory Proteins,Regulatory Proteins, Viral,Accessory Proteins, Viral,Proteins, Viral Accessory,Proteins, Viral Regulatory
D054884 Host-Pathogen Interactions The interactions between a host and a pathogen, usually resulting in disease. Host Pathogen Interaction,Host-Pathogen Relations,Pathogen-Host Interaction,Pathogen-Host Interactions,Host Pathogen Interactions,Host Pathogen Relations,Host-Pathogen Interaction,Host-Pathogen Relation,Interaction, Host Pathogen,Interaction, Host-Pathogen,Interaction, Pathogen-Host,Interactions, Host Pathogen,Interactions, Host-Pathogen,Interactions, Pathogen-Host,Pathogen Host Interaction,Pathogen Host Interactions,Pathogen Interaction, Host,Pathogen Interactions, Host,Relation, Host-Pathogen,Relations, Host-Pathogen
D057074 Virus Release Release of a virus from the host cell following VIRUS ASSEMBLY and maturation. Egress can occur by host cell lysis, EXOCYTOSIS, or budding through the plasma membrane. Virus Budding,Virus Egress,Budding, Virus,Egress, Virus,Release, Virus

Related Publications

Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
January 2011, PloS one,
Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
January 2013, FEBS letters,
Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
April 2014, Proceedings of the National Academy of Sciences of the United States of America,
Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
July 2015, Scientific reports,
Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
December 2016, Journal of virology,
Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
September 2023, Infectious medicine,
Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
July 2020, Journal of virology,
Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
June 2014, Journal of virology,
Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
June 2012, Current HIV research,
Katharina Mack, and Kathrin Starz, and Daniel Sauter, and Simon Langer, and Frederic Bibollet-Ruche, and Gerald H Learn, and Christina M Stürzel, and Marie Leoz, and Jean-Christophe Plantier, and Matthias Geyer, and Beatrice H Hahn, and Frank Kirchhoff
August 2016, Journal of virology,
Copied contents to your clipboard!